VivoSeq
Neurology

Episodic Migraine

6

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Episodic Migraine is an early-stage landscape with 6 programs across 5 companies. The most active players are Ipsen, AbbVie, Merz Pharmaceuticals GmbH. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ipsen logo

Ipsen

3 programs

Phase 2AbbVie logo

AbbVie

2 programs

Phase 3M

Merz Pharmaceuticals GmbH

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3M

Merz Therapeutics GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Recruiting4 · 80%
Not yet recruiting1 · 20%

Clinical Trials

Trial Activity

A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults
Recruiting·Ipsen logoIpsen·Phase 2·NCT06625060·641 enrolled
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.
Recruiting·AbbVie logoAbbVie·Phase 3·NCT05711394·450 enrolled
Chiropractic Care for Episodic Migraine
Recruiting·BBrigham and Women's Hospital·Preclinical·NCT06229834·60 enrolled
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Episodic Migraine
Recruiting·MMerz Therapeutics GmbH·Phase 3·NCT07018700·990 enrolled
Effectiveness of Neurofeedback for Reducing the Frequency and Severity of Episodic Migraine
Not yet recruiting·UUniversity of Salamanca·Preclinical·NCT07661888·66 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)